For most pharmaceutical companies, the honest answer is: “We’re compliant.” And after years of regulatory deadlines, significant capital expenditure, and organizational pain — that is no small achievement. But compliance is only a starting point, and most of the industry has stopped there.

For pharmaceutical companies, the challenge is no longer whether to invest in serialization infrastructure, but how to architect that investment to deliver maximum enterprise value. Forward-thinking pharmaceutical leaders are discovering that a well-designed serialization platform — built on a hybrid architecture, integrated with enterprise systems, and aligned with a scalable digital transformation strategy — can simultaneously satisfy regulators, reduce operational risk, improve data analytics, and enable proactive decision-making.

The current state of the situation for most manufacturers:

Serialization systems are operationally isolated — connected enough to print and scan, disconnected from the enterprise and supply chain decisions that matter. Data flows into the system, but almost none flows back out in a form that creates business value; the integration pushes events without pulling insight. The analytics capability on the roadmap was deprioritized when the compliance deadline was hit.

The result: organizations sitting on one of the richest real-time data streams in their entire enterprise — granular, validated, unit-level supply chain intelligence — and using it only to generate compliance reports. That gap is closing, but not fast enough or uniformly.

The Serialization 1.0 → 2.0 shift

Companies making the serialization 2.0 transition are discovering something that compliance-only framing obscured: the serialized product ID is a universal key. It links manufacturing records, quality events, logistics data, and commercial transactions in ways that were previously impossible. That is a legitimate data infrastructure advantage, extending well beyond compliance.

Understanding where your organization sits today is the prerequisite for planning where you go next. Most of the industry is at Levels 1 and 2. Level 3 is where competitive differentiation begins to compound.

Scalable Digital Transformation Strategies for Pharma Serialization

The four pillars of scalable transformation

The organizations sustaining transformation momentum share four structural characteristics. These are design principles for how the program is built and governed, rather than technology choices.

1- Hybrid architecture as a foundation and global-by-design regulatory landscape

Fully on-premises serialization systems can create technical debt that limits long-term transformation. A hybrid architecture provides a more scalable foundation by combining the resilience of on-premises line and site systems with the elasticity, regulatory velocity, and integration capabilities of cloud platforms.

In this model, critical on-premises components support line continuity, local buffering, and minimal downtime for continuous manufacturing, while cloud services enable enterprise orchestration, global compliance updates, advanced analytics, and API-based ecosystem connectivity. Organizations migrating from fully on-premises serialization environments typically gain a step-change improvement in integration capability while reducing lifecycle complexity and total cost of ownership over time.

Building serialization capabilities market by market, in response to individual compliance deadlines, often created a fragmented architecture that is expensive to maintain and difficult to harmonize. For multinational pharmaceutical manufacturers, this approach limits scalability, increases operational complexity, and slows the organization’s ability to respond to evolving regulatory requirements.

Global-by-design architecture provides a more sustainable model. By using market-specific regulatory adapters on a common cloud platform, organizations can support DSCSA, FMD, NMPA, ANVISA, SFDA, and other market requirements without creating separate, disconnected solutions for each jurisdiction.

• Reference Architecture for Enterprise Serialization

A well-designed hybrid serialization architecture operates across the following functional layers:

• Platform Selection Criteria for Pharma Companies

When evaluating serialization platform vendors, management teams should assess capability across five critical dimensions:

– Regulatory breadth and depth: Does the platform support current and emerging requirements across all relevant markets? What is the vendor’s track record of proactive regulatory updates?

– ERP integration maturity: Is the integration native or does it require significant custom development e.g.,SAP ERP/S4HANA native and pre-certified.

– Scalability and performance SLAs: What are the guaranteed throughputs, and how does the platform handle peak serialization events without impacting production lines?

– Data sovereignty and security posture: For multinational manufacturers, where is data stored and processed? How are data residency requirements for markets like China and Russia handled?

– Total cost of ownership: Beyond licensing fees, what are the implementation, integration, and ongoing operational costs? What is the vendor’s customer success model?

2 – Enterprise system as the operational backbone

Serialization data must flow bidirectionally with other enterprise systems, such as ERP—not just event triggers from ERP, but also quality intelligence, inventory signals, and production analytics flowing back in. The depth of integration determines the value ceiling: shallow integration delivers compliance, while deep, bidirectional integration delivers transformation.

Establish bidirectional data flows between ERP and serialization systems so production orders, batch data, material master data, commissioning events, aggregation status, quality signals, inventory movements, and exception data can move reliably across the enterprise.  The integration between serialization systems and SAP is therefore not merely a technical requirement; it is a strategic imperative that determines whether the full value of serialization investment can be realized.

For most global pharmaceutical manufacturers, SAP is the backbone of enterprise operations — managing everything from production planning and batch management to quality, procurement, and financial consolidation.

3- Cross-Functional Ownership Model & Agile delivery

Technology is rarely the limiting factor in the transformation into pharmaceutical serialization. The more common barriers are organizational: siloed ownership between IT, Quality, Operations, Supply Chain, and Regulatory; underinvestment in change management; and insufficient alignment between the technical implementation team and the business stakeholders who will ultimately capture the value.

Supply Chain, Quality, Regulatory, IT, and Commercial must share ownership — with a C-suite champion providing air cover. Programs owned solely by a single department tend to deliver only a compliance-ready system, while those with broader business ownership deliver long-term competitive advantage. The program and system architecture design predict the outcome more reliably than the selected technology platform does.

Regulated industries can adopt agile delivery within a validation framework — delivering capabilities incrementally while maintaining GxP-compliant documentation using the Computer Software Assurance (CSA) model. This eliminates the binary “big bang vs. do nothing” that stalls transformation in pharma.

Successful transformation programs share several organizational characteristics:

– Company sponsorship with clear business ownership: Serialization programs with a C-suite champion — typically the Chief Supply Chain Officer or Chief Digital Officer — consistently outperform those managed at the IT project level.

– Cross-functional governance: A steering committee with representation from Quality, Regulatory, Supply Chain, IT, and Commercial ensures that the platform is built to deliver business value, not just regulatory compliance.

– Validated Agile Delivery: Regulated industries can adopt agile delivery methodologies within a validation framework — delivering value incrementally while maintaining compliance continuously as required for regulated systems.

4- Data Product Mindset: Beyond Compliance

Serialization data treated as a compliance artifact achieves compliance value. Serialization data treated as a data product — with defined consumers, SLAs, and governance —provides enterprise value. This framing shift determines how the platform gets resourced and evolves. Organizations that have made this shift have found entirely new use cases for serialization data in commercial analytics, predictive analyticssis, and enterprise-wide tracking.

The most sophisticated pharmaceutical manufacturers are using the combination of ERP operational data and serialization event data to drive manufacturing excellence outcomes that go far beyond regulatory compliance:

– Overall Equipment Effectiveness (OEE) optimization: Serialization line performance data, integrated with ERP Production Planning, enables identification of bottlenecks, downtime root cause analysis, and continuous improvement programs that improve throughput while maintaining compliance.

– Predictive quality management: Machine learning models trained on serialization event data — print quality scores, vision system reject rates, line speed patterns — can predict quality deviations before they result in batch failures or compliance events.

– Digital batch records: Integration between serialization systems and Electronic Batch Record capabilities enables the creation of fully connected digital batch records where serialization data is a native component — accelerating batch release and regulatory submissions.

– Supplier quality management: Extending serialization connectivity to component and packaging suppliers enables incoming material verification and closes the loop on supplier quality management programs within ERP.

Action Framework: From Strategy to Execution

The Five Questions Every Pharmaceutical Management Team Should Ask

1. Are we compliant today and flexible for the future?

Understanding not just the current compliance status but also the roadmap of emerging regulatory requirements across all markets over the next 3–5 years is essential for making durable platform investments.

2. How much of the event data your platform captures is being used for business decisions?

If the answer is “almost none beyond compliance reporting,” you have a recoverable asset sitting idle. Commission a 30-day internal assessment before the next budget cycle.

3. Is our architecture scalable for the next decade?

Point solutions deployed for initial compliance often create technical debt that limits future capability. Is the current architecture positioned to support the digital transformation agenda?

4. Is our ERP integration strategic or tactical?

Shallow integrations that simply trigger serialization from ERP process steps miss the full opportunity. Is serialization data flowing bidirectionally to drive quality, supply chain, and commercial outcomes?

5. Do we have the organizational capability to sustain and evolve the platform?

Technology without organizational capability delivers compliance but is not a competitive advantage. Has the organization invested adequately in people, process, and governance?

Recommended Company Actions

For pharmaceutical companies looking to accelerate their serialization and Track & Trace strategy, we recommend the following near-term actions:

Establish Company governance: Elevate serialization ownership to a designated business leader, such as the CSCO or CDO, rather than leaving it solely within IT or compliance. Define clear accountability, decision rights, and cross-functional governance across Supply Chain, Quality, Regulatory, IT, and Commercial.  This governance shift creates the Company alignment needed to turn serialization from a compliance program into an enterprise value driver.

Evaluate cloud migration readiness: On-premises systems deployed for initial compliance are increasingly reaching their limits. If the organization still operates with an on-premises serialization infrastructure, assess both the business case and technical feasibility of migrating to a cloud-native platform within the next 18–24 months.

Advance pharma traceability maturity: Assess the current state of serialization to identify priority gaps across regulatory readiness, line-to-enterprise data flow, aggregation accuracy, exception management, recall responsiveness, and supply chain visibility. Translate these findings into a focused roadmap for the next planning cycle, with clear actions to strengthen performance and enterprise value creation.

Look beyond traditional serialization systems: Avoid over-reliance on vertically integrated, single-vendor serialization platforms that can create long-term vendor lock-in, limit flexibility, and increase lifecycle maintenance costs. Evaluate vendor-agnostic alternatives, including PLC-based aggregation and open integration architectures, where appropriate. These approaches can improve interoperability, reduce long-term upkeep, and provide a more flexible foundation for future traceability, line expansion, and enterprise integration needs.

Prioritize deep integration with ERP systems: Engage ERP and serialization platform owners early to define a strategic integration roadmap that goes beyond basic event triggering or compliance reporting. This depth of integration allows both investments to create greater value by improving operational visibility, reducing manual reconciliation, strengthening traceability controls, and enabling data-driven decisions across manufacturing, quality, supply chain, and commercial operations.

The Bottom Line

The pharmaceutical industry has made a massive, necessary investment in serialization infrastructure. The compliance mandate is real, the implementation was hard, and the organizations that got there deserve credit.

But the window for competitive differentiation is open right now — and it will not stay open indefinitely. The gap between pharma companies that treat serialization as a filing cabinet and those that treat it as a strategic platform will widen over the next five years.